Overview
A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I)
Status:
Completed
Completed
Trial end date:
2009-09-01
2009-09-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This was a double-blind, placebo-controlled, parallel-arm, multicentre, prospective dose-finding trial of the safety and efficacy of atacicept in subjects with active rheumatoid arthritis who had failed a three month therapeutic trial with a tumor necrosis factor alpha (TNFa) antagonist due to lack of efficacy.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
EMD SeronoCollaborators:
Merck KGaA
Merck KGaA, Darmstadt, Germany
Criteria
Inclusion Criteria:1. Rheumatoid arthritis (RA) satisfying American College of Rheumatology (ACR) diagnostic
criteria with a disease history of at least one year
2. Male or female greater than or equal to (>=)18-years of age at time of informed
consent
3. Active RA as defined by:
- >=8 swollen joints (66-joint count),
- >=8 tender joints (68-joint count), and
- C-reactive protein (CRP) >=10 milligram per liter (mg/L) (central laboratory)
and/or erythrocyte sedimentation rate (ESR) >= to 28 millimeter per hour (mm/h)
4. Failure of at least one TNFa antagonist therapy (previously or at the time of
screening) as specified in the protocol
5. Other protocol defined inclusion criteria could apply
Exclusion Criteria:
1. Any condition, including laboratory findings or findings in the medical history or
pre-trial assessments, that in the opinion of the Investigator constitutes a risk or a
contraindication for the subject's participation in the trial or that could interfere
with the trial objectives, conduct or evaluation
2. Treatment with biologics aiming at B cell modulation such as rituximab or belimumab
within 2 years before study Day 1
3. Any previous treatment with anakinra (Kineret), abatacept (Orencia) or tocilizumab
within 3 months before study Day 1
4. Use of etanercept (Enbrel) within 28 days before study Day 1, or of infliximab
(Remicade) or adalimumab (Humira) within 60 days before study Day 1
5. Participation in any interventional clinical trial with an unapproved investigational
therapy within the 3 months before the start of this study (or within 5 half-lives of
the investigated compound before study Day 1, whichever is longer)
6. Other protocol defined exclusion criteria could apply